News & Updates
Filter by Specialty:
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
20 Dec 2022
Metformin may reduce COVID-19 severity in prediabetes, PCOS
Among patients with prediabetes or polycystic ovary syndrome (PCOS), the use of metformin appears to be associated with lower incidence of severe COVID-19, according to a study.
Metformin may reduce COVID-19 severity in prediabetes, PCOS
19 Dec 2022
Bepirovirsen shows promise in controlling chronic HBV infection
Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.
Bepirovirsen shows promise in controlling chronic HBV infection
19 Dec 2022
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
